Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07533175 · ClinicalTrials.gov registry record · Phase 3
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 630
- Enrollment target
NCT07533175 is a Phase 3 study that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 630 participants.
The verdict
NCT07533175, a Phase 3 study, is actively recruiting participants, sponsored by Novo Nordisk A/S.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 630 participants
- Enrollment target
Study Summary
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (treatment that has no active medicine in it). Which treatment participants get is decided by chance.
Interventions
- DRUG NNC0487-0111
- DRUG Placebo (matched to NNC0487-0111)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 630 participants |
| Start Date | 2026-04-13 |
| Est. Completion | 2028-08-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07533175
The ClinicalTrials.gov registry entry for NCT07533175 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 630 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which NNC0487-0111 is the first listed.
NCT07533175 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07533175 about?
NCT07533175 is a clinical study titled "AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight". The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treat...
What is the current status of trial NCT07533175?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 630 participants. The study started on 2026-04-13. Estimated completion is 2028-08-07.
What interventions are being tested in trial NCT07533175?
The interventions under investigation include: NNC0487-0111 (DRUG), Placebo (matched to NNC0487-0111) (DRUG).
Who is sponsoring clinical trial NCT07533175?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.